Doyle Mittie 4

What Happened
Doyle Mittie, Chief Medical Officer of Avalo Therapeutics (AVTX), had 1,084 shares disposed on 2026-06-10 to satisfy tax withholding (transaction code F). The shares were reported disposed at $13.10 per share for proceeds of approximately $14,200. The filing also notes that 5,738 shares were acquired pursuant to the issuer's Employee Stock Purchase Plan as part of this reporting transaction, meaning the withholding occurred in connection with an ESPP purchase.

Key Details

• Transaction date: 2026-06-10; filing date: 2026-06-12 (timely within Form 4 rules).
• Disposed: 1,084 shares at $13.10/share — proceeds ≈ $14,200 (code F: tax withholding).
• Footnote: Includes 5,738 shares acquired under the Employee Stock Purchase Plan as part of this reporting transaction.
• Net effect (based on reported numbers): 5,738 acquired − 1,084 withheld = net +4,654 shares acquired (if both actions relate to the same ESPP purchase).
• Shares owned after transaction: not specified in the Form 4 filing.

Context
Code F transactions are routine tax-withholding actions tied to share acquisitions (often from ESPP purchases or option exercises) and are not the same as an open-market sale by the insider. The filing shows an ESPP purchase occurred and that a portion of those shares were surrendered to cover taxes; this is primarily administrative and does not necessarily signal the insider’s view on the company’s stock.